Schneider Felicitas Magdalena, Pochert Nicole, Schittek Fritzi, Köpke Melitta Beatrice, Wild Carl Mathis, Veh Johanna Marie, Rohrmoser Natalie Renate, Kuhn Christina, Urban Birgit, Kahl Klaus-Henning, Schneider Mariella, Mattmer Angelika, Hinske Ludwig Christian, Fluhrer Regina, Golas Monika M, Untch Michael, Kuehn Thorsten, Banys-Paluchowski Maggie, Jeschke Udo, Traidl-Hoffmann Claudia, Dannecker Christian, Ditsch Nina
Gynecology, Obstetrics and Senology, Faculty of Medicine, University of Augsburg, Stenglinstraße 2, 86156, Augsburg, Germany.
Helmholtz Center Munich, Institute of Environmental Medicine, German Research Center for Environmental Health, Neuherberg, Germany.
Sci Rep. 2025 Sep 12;15(1):32442. doi: 10.1038/s41598-025-17139-2.
Seroma formation is a frequent complication following mastectomy in the surgical treatment of breast cancer with profound consequences for the patients including possibly quality of life impairing implant complications. The pathogenesis remains unknown, leading to a lack of efficient preventive and curative strategies. The study's objective was to determine whether the macrophage infiltration of the tumor microenvironment and surrounding adipose tissue at the time of primary surgery is associated with postoperative seroma development. The observational monocentric SerMa pilot study was conducted from 12/2019 to 12/2022. We included 91 breast cancer and 9 carcinoma in situ cases treated with mastectomy at the University Hospital Augsburg, Germany. Patients with previous malignancies, metastatic disease and known immunodeficiency were excluded. The patients underwent different mastectomy procedures with or without implant- or expander-based breast reconstruction. The study's main outcome was seroma formation up to six months post-surgery, determined by clinical examination and fine needle aspiration of the seroma fluid if clinically necessary. Macrophage markers (CD68 and CD163) were immunohistochemically determined in formalin fixed paraffin-embedded slides containing the primary tumor and surrounding adipose tissue. Two groups were then formed as independent variables: cases with (seroma +) and without postoperative seroma formation (seroma-). Since all parameters in this study were not normally distributed, the non-parametric Mann-Whitney-U-test was used. A p-value < 0.05 was considered statistically significant. CD68 + cells (cases with seroma (seroma +): median = 90.7 cells, IQR = 62.5-130.5; cases without seroma (seroma-): median = 64.3 cells, IQR = 47.0-115-0, p = 0.036) and CD163 + cells (seroma + : median = 58.3 cells, IQR = 33.0-91.4; seroma-: median = 40.7 cells, IQR = 28.3-55.3, p = 0.027) in the tumor microenvironment and in the surrounding adipose tissue (CD68 + cells (seroma + : median = 8.0 cells, IQR = 5.3-11.0; seroma-: median = 4.7 cells, IQR = 3.0-10.0, p = 0.013), CD163 + cells (seroma + : median = 11.0 cells, IQR = 6.7-15.0; seroma-: median = 6.7 cells, IQR = 3.0-9.7, p = 0.016)) were significantly higher in cases with postoperative seroma formation compared to cases without. In the SerMa pilot study macrophage polarization within the primary tumor and surrounding adipose tissue was associated with post-operative seroma formation in breast cancer patients. This might be a suitable biomarker for predicting a higher risk of seroma formation.
血清肿形成是乳腺癌手术治疗中行乳房切除术后常见的并发症,对患者有深远影响,包括可能影响生活质量的植入物相关并发症。其发病机制尚不清楚,导致缺乏有效的预防和治疗策略。本研究的目的是确定初次手术时肿瘤微环境和周围脂肪组织中的巨噬细胞浸润是否与术后血清肿的发生有关。这项单中心观察性SerMa初步研究于2019年12月至2022年12月进行。我们纳入了德国奥格斯堡大学医院91例接受乳房切除术的乳腺癌患者和9例原位癌患者。排除既往有恶性肿瘤、转移性疾病和已知免疫缺陷的患者。患者接受了不同的乳房切除手术,包括有或没有基于植入物或扩张器的乳房重建。本研究的主要结局是术后六个月内血清肿的形成,通过临床检查确定,必要时对血清肿液进行细针穿刺抽吸。在含有原发性肿瘤和周围脂肪组织的福尔马林固定石蜡包埋切片中,通过免疫组织化学方法测定巨噬细胞标志物(CD68和CD163)。然后将两组作为自变量:有术后血清肿形成的病例(血清肿阳性)和无术后血清肿形成的病例(血清肿阴性)。由于本研究中的所有参数均非正态分布,因此使用非参数曼-惠特尼U检验。p值<0.05被认为具有统计学意义。与无血清肿形成的病例相比,有术后血清肿形成的病例中肿瘤微环境和周围脂肪组织中的CD68 +细胞(血清肿阳性:中位数=90.7个细胞,四分位间距=62.5-130.5;血清肿阴性:中位数=64.3个细胞,四分位间距=47.0-115.0,p = 0.036)和CD16 +细胞(血清肿阳性:中位数=58.3个细胞,四分位间距=33.0-91.4;血清肿阴性:中位数=40.7个细胞,四分位间距=28.3-55.3,p = 0.027)显著更高(CD68 +细胞(血清肿阳性:中位数=8.0个细胞,四分位间距=5.3-11.0;血清肿阴性:中位数=4.7个细胞,四分位间距=3.0-10.0,p = 0.013),CD163 +细胞(血清肿阳性:中位数=11.0个细胞,四分位间距=6.7-15.0;血清肿阴性:中位数=6.7个细胞,四分位间距=3.0-9.7,p = 0.016))。在SerMa初步研究中,原发性肿瘤和周围脂肪组织内的巨噬细胞极化与乳腺癌患者术后血清肿的形成有关。这可能是预测血清肿形成较高风险的合适生物标志物。